We examined whether, in human obesity and type 2 diabetes, long chain fatty acid (LCFA) transport into skeletal muscle is upregulated and contributes to an excess intramuscular triacylglycerol accumulation. In giant sarcolemmal vesicles prepared from human skeletal muscle, LCFA transport rates were upregulated ~4-fold and were associated with an increased intramuscular triacylglycerol content in obese individuals and in type 2 diabetics. In these individuals, the increased sarcolemmal LCFA transport rate was not associated with an altered expression of FAT/CD36 or FABPpm. Instead, the increase in the LCFA transport rate was associated with an increase in sarcolemmal FAT/CD36 but not sarcolemmal FABPpm. Rates of fatty acid esterification were increased threefold in isolated human muscle strips obtained from obese subjects, while concomitantly rates of fatty acid oxidation were not altered. Thus, the increased rate of fatty acid transport may contribute to the increased rates of triacylglycerol accumulation in human skeletal muscle. The altered FAT/CD36 trafficking in muscle from obese subjects and type 2 diabetics juxtaposes the known alterations in GLUT4 trafficking, i.e., GLUT4 is known to be retained in its intracellular depots while FAT/CD36 is retained at the sarcolemma. This redistribution of FAT/CD36 to the sarcolemma may contribute to the etiology of insulin resistance in human muscle, and hence, FAT/CD36 provides another potential therapeutic target for the prevention and/or treatment of insulin resistance.
he lipid milieu of skeletal muscle is one factor that contributes to insulin resistance in this tissue. For example, the accumulation of intramuscular triacylglycerols (1, 2) and long chain acyl-CoA esters (3), as well as an increase in circulating long chain fatty acids (LCFA; refs 4, 5) , has been associated with skeletal muscle insulin resistance in animals and humans. In insulin-resistant skeletal muscle of obese Zucker rats (6) and obese humans (7) , rates of palmitate esterification are markedly increased. Concurrently, the rates of LCFA oxidation are reduced in rodent obesity (6) , whereas in human obesity and type 2 diabetes there is conflicting evidence as to whether rates of fatty acid oxidation are reduced (7, 8, 9, 10) . These studies imply that intracellular skeletal muscle LCFA metabolism in obesity and diabetes is repartitioned away from oxidation and toward storage.
In addition to the increased rates of LCFA esterification and reduced rates of LCFA oxidation, an increased rate of LCFA flux across the sarcolemma may also contribute to the triacylglycerol accumulation that occurs in human obesity and type 2 diabetes. We (11, 12) have shown that the rate of LCFA uptake across the plasma membrane is a key step regulating intramuscular LCFA metabolism in rodent skeletal muscle (11, 12) . Although it was believed for many years that LCFAs crossed the plasma membrane via passive diffusion (13) , the emerging view is that LCFAs also cross the plasma membrane via a protein-mediated mechanism, involving a number of fatty acid binding proteins (14, 15, 16, 17) . Among these are the integral membrane protein, fatty acid translocase (FAT/CD36, the rat homologue of human CD36; refs 11, 18, 19, 20, 21) , and the peripheral, plasma membrane-associated fatty acid binding protein (FABPpm; refs 11, 22, 23) . The role of fatty acid transport protein 1 (FATP1; ref 24) in this process is less certain since a number of studies have reported that FATP1 is a very long chain fatty acyl CoA synthase (25, 26). We (19, 27) have recently shown that sarcolemmal LCFA transport is a dynamic process, since muscle contraction (19) and insulin (27) can rapidly increase LCFA transport into skeletal muscle (i.e., within minutes). This has been associated with the translocation of FAT/CD36 from an intracellular depot to the plasma membrane. Additionally, our work has shown that sarcolemmal fatty acid transport is increased in animal models of insulin resistance (28) and insulin insufficiency (29) and is decreased in a model (30) of improved insulin sensitivity (31) . These changes in vesicular LCFA transport are associated with an altered expression and/or permanent relocation of LCFA transporters within the myocyte (28, 29, 31).
There is very limited information on LCFA transporters in human skeletal muscle. We have shown that FAT/CD36 and FABPpm are coexpressed in human muscle (32) , and others have shown that FABPpm protein content is increased with exercise training (33) and in human obesity (34) . Although it has been reported that FATP1 mRNA was decreased in obese individuals, with and without type 2 diabetes (35), we (28, 36) and others (37, 38) have observed that the mRNA abundance of LCFA transporters does not show a good relationship with either LCFA transport protein expression or LCFA transport. Rather, it is important to examine changes in LCFA transport in relation to the plasmalemmal location of LCFA transport proteins (19, 28, 29, 31) . Indeed, based on our animals studies, we (28) have recently proposed that analogous to the impaired cycling of the glucose transporter GLUT4 from intracellular depots to the cell surface (39) , FAT/CD36 cycling is also impaired in insulin-resistant skeletal muscle, with FAT/CD36 being retained at the cell surface, which results in an increased rate of LCFA transport.
To date, rates of LCFA transport into human skeletal muscle have not been examined in either healthy individuals or in obesity and type 2 diabetes. Moreover, it is not known whether LCFA transport rates are related to the degree of triacylglycerol accumulation in muscle. Therefore, we have examined in skeletal muscle of lean, overweight, and obese individuals and individuals with type 2 diabetes, 1) the rates of LCFA transport into giant sarcolemmal vesicles, 2) the expression of the LCFA transport proteins FAT/CD36 and FABPpm in muscle homogenates (i.e., total LCFA transport proteins), and their localization at the plasma membrane (i.e., at the site where these proteins facilitate LCFA transport); 3) the rates of LCFA esterification in isolated human muscle in vitro; and 4) we compared rates of LCFA transport and transporters with triacylglycerol accumulation in skeletal muscle. Our studies show that the excess accumulation of intramuscular triacylglycerol in obesity and diabetes is strongly associated with an upregulation of the fatty acid transport rates across the sarcolemma. This increased fatty acid transport rate is not associated with an increased expression of the fatty acid transporters, but rather, is associated with the increased presence of FAT/CD36, but not FABPpm, at the plasma membrane.
METHODS
The participants (n=33) included men and women. They were subdivided on the basis of body mass index (BMI) into lean (BMI<25), overweight (BMI: 25-30) or obese (BMI>30). In addition, type 2 diabetics were identified from clinical diagnosis. The resultant groups were as follows: lean (n=11, 3 men and 8 women; BMI: 21.8±0.6), overweight (n=10; 3 men and 7 women; BMI: 26.9±0.5), obese (n=7; 1 man and 6 women; BMI: 34.7±1.7) and type 2 diabetes (n=5; 1 man and 4 women; BMI: 25.6±1.1; Table 1 ). These individuals were admitted to McMaster Health Sciences Center for a variety of abdominal surgical interventions. They all provided written, informed consent before participating in the present study. The experimental procedures were approved by the McMaster University Ethics Committee. Body mass for all individuals had essentially been maintained in the year preceding the study. After an overnight fast (16-18 h), general anesthesia was induced with a short-acting barbiturate and maintained by a fentanyl and rocuronium volatile anesthetic mixture. Venous blood samples were then obtained during anesthesia. Once muscles were exposed during surgery, a small sample of the rectus abdominus muscle was excised and placed in oxygenated, ice-cold Krebs-Henseleit buffer for transport to the laboratory (~5 min). At that point, a small section of muscle was frozen in liquid nitrogen while the remainder of the sample was used to prepare giant sarcolemmal vesicles. In some lean and obese individuals, sufficient tissue was obtained from which to prepare intact muscle strips to determine rates of palmitate oxidation an esterification in vitro. Several other studies have also examined substrate metabolism in samples of human muscle obtained during abdominal surgery (7, 40, 41, 42) .
Giant sarcolemmal vesicle preparation
Vesicles from human muscles were prepared as we have described for rodent muscles (11, 19, 28) . Briefly, muscle samples were cut into thin layers (~1-3 mm thick) and incubated for 1 h at 34°C in 140 mM KCl/10 mM MOPS (pH 7.4), collagenase (150 U/ml), and aprotinin (0.01 g/ml). The muscle was then washed with KCl/MOPS, supplemented with 10 mM EDTA, and the supernatant was collected. Percoll (final concentration 16%) and aprotinin were added to the supernatant. This supernatant was placed at the bottom of a density gradient consisting of a 3 ml middle layer of 4% Nycodenz (wt/vol) and a 1 ml KCl/MOPS upper layer. The samples were spun at 60 g for 45 min at room temperature. After centrifugation, the vesicles were harvested from the interface of the two upper solutions. The vesicles were diluted in KCl/MOPS and recentrifuged at 800 g for 30 min. Vesicles were immediately used for transport experiments. A portion of the vesicles was also stored at -80°C for analyses of plasma membrane FAT/CD36 and FABPpm by Western blotting.
Fatty acid transport
Palmitate uptake was measured by the addition of unlabeled palmitate (Sigma-Aldrich, St. Louis, MO) and [ 3 H]palmitate (0.3 µCi), and [ 14 C]mannitol (0.06 µCi; Amersham, Mississauga, Ontario) in a 0.1% BSA KCl/MOPS solution to 40 µl of vesicles (~80 µg protein). The reaction was carried out at room temperature for 15 s. Palmitate uptake was terminated by addition of 1.4 ml ice-cold KCl/MOPS, containing 2.5 mM HgCl and 0.1% BSA. The sample was quickly centrifuged at maximal speed in a microfuge for 1 min. The supernatant was discarded, and radioactivity was determined in the tip of the tube. Nonspecific uptake was measured by adding the stop solution to the membrane before the addition of the isotopes.
Fatty acid esterification
In some individuals (lean, n=9; obese n=6), we were able to determine the rates of palmitate oxidation and incorporation into intramuscular triacylglycerols in isolated strips of human muscle obtained during surgery. Methods for these determinations have been published previously (12, 43) and were identical to those published in a previous study involving human subjects (7).
Protein determinations
FAT/CD36 and FABPpm protein were determined in muscle homogenates and in plasma membranes of the giant sarcolemmal vesicles by using Western blotting as we have described previously (11, 19, 28) . For detection of FAT/CD36 and FABPpm, we used the antibody MO-25 (44) and a rabbit polyclonal anti-FABPpm antiserum (45) , respectively. The concentration of cytoplasmic FABP (H-FABP) in muscle homogenates was determined by a sandwich-type ELISA as described previously (46) .
Other measurements
Skeletal muscle triacylglycerol content was measured on freeze-dried muscle tissue, from which visible fat and connective tissue had been removed, using an enzymatic procedure, as we have previously reported (47) . Circulating glucose and glycerol concentrations were determined as described by Bergmeyer (48) . Serum insulin, leptin (LINCO, St. Charles, MO), and fatty acids (WAKO Chemicals, Osaka, Japan) were measured using commercially available kits.
Statistical analyses
The data were analyzed using analyses of variance and a least squares difference (LSD) post-hoc test. All data are means ± SE.
RESULTS
There were no differences in the ages of the participants, except for the type 2 diabetics, who were older than the lean and overweight subjects (Table 1) . However, no relationships were found between the ages of the participants and any of the parameters that were measured in this study. Compared with the lean subjects, greater body weights were observed in the overweight (+18%) and obese individuals (+49%) but not the type 2 diabetics (Table 1) . BMI in the lean group was lower than in each of the other three groups (P<0.05; i.e., overweight BMI: +23%; obese BMI: +59%; type 2 diabetics BMI: +17%).
Circulating glucose (P<0.05) and insulin concentrations (P<0.05) were higher in the type 2 diabetics, when compared with the other subjects ( Table 1) . With the prolonged fast (16-18 h), no differences in circulating fatty acids and insulin were observed among the lean, overweight, and obese subjects (P>0.05; Table 1 ). This confirms previous results in similar groups of lean and obese individuals who had undergone a similar fast before surgery (7) . The circulating leptin concentrations were greater in the obese subjects compared with the lean and overweight subjects and greater in the type 2 diabetics when compared with the lean individuals ( Table 1) .
Fatty acid transport into giant sarcolemmal vesicles
Palmitate transport rates were measured in giant sarcolemmal vesicles prepared from skeletal muscle, as we have done routinely in our animal studies (11, 19, 28, 31) . Rates of palmitate transport into giant sarcolemmal vesicles did not differ in lean and overweight individuals (P>0.05; Fig. 1 ). However, in comparison to the lean subjects, the rates of palmitate transport were greatly increased in the obese individuals (3.8-fold; P<0.05; Fig. 1 ) and in the type 2 diabetics (4.3-fold; P<0.05; Fig. 1 ). These increased rates of palmitate transport in obese subjects and type 2 diabetics did not differ (P>0.05; Fig. 1 ). Differences in LCFA transport rates were not attributable to the intramuscular fatty acid sink, H-FABPc, since its concentrations were not different among the groups (P>0.05, Table 1 ).
Fatty acid transporters, FABPpm and FAT/CD36, in homogenates and the plasma membrane FABPpm
No differences in homogenate FABPpm were observed between the lean and type 2 diabetics (P>0.05, Fig. 2A and B) , whereas in the obese subjects the total FABPpm in muscle homogenates was reduced by 30% in comparison to the lean subjects (P<0.05; Fig. 2A and B) . However, there were no differences in the plasma membrane FABPpm content among the four groups (P>0.05, Fig. 2A and D) .
FAT/CD36
Homogenate FAT/CD36 did not differ among the four groups ( Fig. 2A and C) . In contrast, the plasma membrane FAT/CD36 in comparison to the lean and overweight subjects was increased in the obese individuals (+40%; P<0.05) and in the type 2 diabetics (+76%; P<0.05; Fig. 2A and E). Plasma membrane FAT/CD36 in the lean and overweight subjects did not differ (P>0.05; Fig. 2A and E) . There was a positive association between plasma membrane FAT/CD36 and rates of palmitate transport (Fig. 3) .
Skeletal muscle triacylglycerol concentration and rates of fatty acid esterification and oxidation
In muscle trimmed of visible fat, triacylglycerol content was not different in lean and overweight individuals ( Fig. 4A; P>0.05) . In contrast, the triacylgycerol content was twofold greater in the obese subjects and threefold greater in the type 2 diabetics (Fig. 4A; P<0.05) . Intramuscular triacylglycerol concentrations did not differ between obese subjects and type 2 diabetics (Fig.  4A; P>0.05) . In isolated muscle strips incubated in vitro, the rates of palmitate metabolism were also increased. This was associated with a threefold increase in the rate of palmitate esterification ( Fig. 4B; P<0.05) , since the rate of palmitate oxidation was not altered (Fig. 4C; P>0.05) . Rates of palmitate transport (Fig. 5A ) and plasmalemmal FAT/CD36 (Fig. 5B) were positively associated with intramuscular triacylglycerol concentrations.
DISCUSSION
This is the first study in which the rates of fatty acid transport across the sarcolemma have been examined in giant sarcolemmal vesicles obtained from human skeletal muscle. We have previously shown that these sarcolemmal vesicles are suitable for examining protein-mediated fatty acid transport in the absence of any confounding effects of fatty acid metabolism (11, 19, 27, 28, 29, 31, 49) . At present there are no other suitable preparations with which to examine rates of sarcolemmal fatty acid transport into rodent or human skeletal muscle.
There are a number of novel observations in the present study. These are as follows: 1) at a given concentration of palmitate, the palmitate transport rate into giant sarcolemmal vesiscle is markedly upregulated (3.8-to 4.3-fold) in human obesity and type 2 diabetes, but, 2) this increase in sarcolemmal LCFA transport is not associated with an increase in the total expression of either FAT/CD36 or FABPpm, but rather 3) the increase in LCFA transport is associated with an increase in plasmalemmal FAT/CD36, but not plasmalemmal FABPpm. In addition, 4) skeletal muscle triacylglycerol concentrations were increased two-to three-fold in obese subjects and type 2 diabetics, which may be due in part to 5) markedly increased rates of LCFA esterification. There were 6) positive associations between skeletal muscle triacylglycerol depots and i) rates of LCFA transport into the giant vesicles and ii) FAT/CD36 protein at the plasma membrane. These data indicate that in human obesity and type 2 diabetes, a key perturbation is the subcellular relocation of FAT/CD36 to the sarcolemma, which may contribute to an increased rate of LCFA transport into skeletal muscle and an apparent increase in the excess accumulation of intramuscular triacylglycerols, as the excess LCFAs taken up into the muscle are esterified.
Altered LCFA metabolism and sarcolemmal transport
A number of studies in recent years have implicated changes in the LCFA milieu and LCFA metabolism with impaired insulin sensitivity in skeletal muscle. For example, increased circulating levels of fatty acids (4, 5) and intramuscular triacylglycerol (2) and fatty acyl CoA accumulation (3) have been associated with insulin resistance in skeletal muscle. Recently, it was reported that protein-mediated fatty acid uptake was reduced in muscle cells in culture obtained from type 2 diabetics (50). However, these cells are metabolically active, which may confound rates of LCFA transport, a concern that led us to develop the giant sarcolemmal vesicles in which protein-mediated fatty acid transport can be examined in the absence of LCFA metabolism (11, 49) . Currently, there are no other reports available, either in human type 2 diabetes or in animal models of type 2 diabetes, in which LCFA transport has been examined in vesicle preparations, in which the confounding effects of LCFA metabolism are absent. However, the present studies in obese humans and type 2 diabetics concur with our previous studies in obese Zucker rats (28) and indicate that an increase in the LCFA transport rate is another disturbance in the lipid handling that can occur in skeletal muscle in obesity and type 2 diabetes.
To examine the mechanism accounting for the increase in LCFA transport rates in insulinresistant muscle, we examined changes in the total available pool of FABPpm and FAT/CD36, as well as the changes in the plasmalemmal content of FABPpm and FAT/CD36. It is important to do so since 1) FABPpm, for unknown reasons, is identical to mitochondrial aspartate aminotransferase (51, 52) , and 2) we (19, 27) have reported that FAT/CD36 is present in an intracellular pool and the plasma membrane. Therefore, it is essential to examine FABPpm and FAT/CD36 at the level of the sarcolemma to associate them with LCFA transport. Although Simoneau et al. (34) have found that homogenate FABPpm was increased in muscle from obese humans, this was not observed in the present study, nor in studies with obese Zucker rats (28). Moreover, the observed increases in LCFA transport rates into skeletal muscle from obese individuals and type 2 diabetics (present study), as well as obese Zucker rats (28), were not associated with an increase in plasmalemmal FABPpm. Although the total available pool of FAT/CD36 (i.e., plasmalemmal FAT/CD36 + intracellular FAT/CD36) was not altered, there was however an increase in plasmalemmal FAT/CD36 that was strongly associated with an increased rate of LCFA transport in humans with obesity and with type 2 diabetes (present study), as has previously been observed in obese Zucker rats (28). This suggests that the increase in plasmalemmal FAT/CD36 accounted for the increase in LCFA transport, since in FAT/CD36 null mice rates of LCFA uptake by heart and muscle are significantly reduced (53) , whereas in transgenic mice that overexpress FAT/CD36, LCFA utilization is increased (20).
Impaired FAT/CD36 cycling in obesity and type 2 diabetes
The expression of FABPpm and its plasmalemmal content were not altered in muscle from obese individuals and type 2 diabetics. Similarly, FAT/CD36 expression was also not altered, but importantly, the plasmalemmal FAT/CD36 content was increased in muscle from obese individuals and type 2 diabetics (present study and ref 28). Collectively, these data suggest that the normal cycling of this transporter between the sarcolemma and its intracellular depot has been altered chronically. FAT/CD36 cycling between the plasmalemma and intracellular depots has only recently been shown (19, 27, 36). The contraction-stimulated translocation of FAT/CD36 appears to involve signaling through AMP-kinase (54), whereas the insulin-induced translocation of FAT/CD36 occurs via PI3-kinase signaling (27, 36). Other downstream contraction-and insulin-stimulated signaling proteins involved in FAT/CD36 translocation remain to be identified. The signals involved in chronically altering the subcellular redistribution of FAT/CD36 in obesity and type 2 diabetes are not known presently.
The impairment of FAT/CD36 cycling between subcellular compartments is reminiscent of a similar disturbance in the insulin-responsive glucose transport system. It is well known that GLUT4 cycling between the cell surface and intracellular depots is impaired in skeletal muscle in obesity and type 2 diabetes, despite similar levels of total available GLUT4 (39, 55) .
Interestingly, the impairments in FAT/CD36 and GLUT4 cycling are juxtaposed. In obesity and type 2 diabetes FAT/CD36 is retained at the cell surface, whereas GLUT4 is retained within the intracellular depots. Given the strong association between LCFA transport and a marker of insulin resistance (triacylglycerol), it is tempting to speculate that there may be cross-talk between the FAT/CD36 and GLUT4 signaling pathways.
Contradictions in the literature, with respect to the relationship between FAT/CD36 and insulin resistance in animal models (21, 53, 56, 57, 58) and humans (59, 60) , may have arisen from attempts to associate the expression of FAT/CD36 with insulin resistance. However, animal studies have shown that in skeletal muscle FAT/CD36 can cycle between the plasma membrane and its intracellular depot (19, 28). Since it is the plasmalemmal location of FAT/CD36 that facilitates LCFA flux into the myocyte, it is this plasmalemmal content of FAT/CD36 that is critical, not necessarily its total pool (intracellular + sarcolemmal; present study and ref 28). Thus, just as a lack of change in the total GLUT4 pool is not always indicative of changes in glucose transport, it also appears that a lack of changes in the total FAT/CD36 pool is not always indicative of a change in LCFA transport.
Increased fatty acid transport increases triacylglycerol concentrations in muscle
The positive association between LCFA transport and triacylglycerol concentrations in skeletal muscle, combined with the increased rate of palmitate esterification in muscle from obese individuals insulin (present study; ref 7) , suggests that the increased LCFAs transported into muscle are stored as triacylglycerols, particularly since skeletal muscle LCFA oxidation is not altered in moderate obesity (present study; refs 7, 42). It appears, however, that skeletal muscle LCFA oxidation is reduced in extremely obese individuals (BMI=54; ref 42) . Presumably, the additional influx of fatty acids into the muscle cell (present study) may also account, in part, for the increase in intramuscular long chain acyl-CoA esters that have been observed in obesity and type 2 diabetes (3, 42).
We propose (Fig. 6) , based on the available evidence, that the intramuscular triacylglycerol concentrations in obesity and type 2 diabetes are attributable to an increase in plasmalemmal FAT/CD36. This increase in plasmalemmal FAT/CD36 then serves to increase the rate of LCFA transport into the muscle cell, where the excess LCFAs taken up are primarily stored as triacylglycerols, particularly since the rate of LCFA esterification is increased while the rate of LCFA oxidation is generally not altered in skeletal muscle of obese individuals (present study; refs 7, 42). Excess intramuscular triacylglycerol accumulation has been associated with impairments in insulin signaling in human obesity and type 2 diabetes, although triacylglycerol depots are most likely a surrogate measure of other fatty acid metabolites that interfere with insulin signaling in muscle (61) .
Circulating substrates and hormones
We opted not to compare changes in LCFA transport and transporters with circulating concentrations of substrates and hormones. The reasons are that the subjects 1) were older, 2) had undergone a prolonged period of fasting (16-18 h), and 3) were under general anesthesia when blood samples were obtained. All these factors together may have altered the normal substrate endocrine milieu. This seems to be the case for fatty acids that, for unknown reasons, were elevated. Insulin resistance was still evident in the type 2 diabetics, as both their glucose and insulin concentrations were greater than in the other groups.
SUMMARY
We have found that LCFA transport rates into skeletal muscle are increased in obese and type 2 diabetics. This is associated with an increased retention of FAT/CD36 at the sarcolemma, indicating that the FAT/CD36 cycling between the plasma membrane and its intracellular compartment has been altered in obesity and type 2 diabetes. The positive relationship between LCFA transport and triacylglycerol content in skeletal muscle provides strong evidence that the augmented LCFA transport rate leads to an excess accumulation of triacylglycerols, a marker of insulin resistance in muscle, particularly since rates of LCFA oxidation in insulin-resistant muscles are not altered, while LCFA esterification rates are markedly increased. It appears that the subcellular redistribution of FAT/CD36 and the associated increase in LCFA transport may be important mechanisms that can contribute to the development of insulin resistance in skeletal muscle. Thus, FAT/CD36 provides another potential therapeutic target for the prevention and/or treatment of insulin resistance. Equal amounts of protein were loaded into each lane. *P < 0.05, lean vs. obese or type 2 diabetes; **P < 0.05, overweight vs. obese or type 2 diabetes; ***P < 0.05, obese vs. type 2 diabetes. Relationship between plasma membrane FAT/CD36 and palmitate transport into giant sarcolemmal vesicles in lean, overweight, and obese individuals and in type 2 diabetics (means ± SE; data are plotted from Fig. 1 and Fig. 2D ).
Page 18 of 21 (page number not for citation purposes) diabetics and rates of palmitate esterification (B) and oxidation (C) in lean and obese subjects (means ± SE; ND = not determined, as samples for overweight and type 2 diabetics were not available). *P < 0.05, lean vs. obese; **P < 0.05, type 2 diabetes vs. obese. cycles between an intracellular compartment and plasma membrane. At plasma membrane, FAT/CD36 assists LCFAs to cross into the cell to be oxidized (CO 2 ) or stored as triacylglycerols (TAG). Right panel: In muscle from obese subjects and type 2 diabetics, the total pool of FAT/CD36 is not altered, but plasmalemmal FAT/CD36 is increased. This permits an increased rate of LCFA transport across sarcolemma. Increased influx of LCFAs into myocyte increases intramuscular concentration of triacylglycerols, since it was shown that rates of LCFA esterification are increased, while the rate of LCFA oxidation is not altered (note heavier arrows denote changes in muscle of obese subjects and type 2 diabetics).
